相关实验视频
Updated: Feb 6, 2026
09:09
In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
2.3K
在罕见疾病的I期临床试验中,患者在剂量升级方面的退缩
1Department of Statistics and Actuarial Science, The University of Hong Kong, Hong Kong, China.
Statistics in medicine
|February 5, 2026
概括
新的剂量确定方法,患者在剂量升级中的退缩 (PRIDE) 和PRIDE-FA,改善了罕见疾病临床试验中的最大耐受剂量 (MTD) 识别. 这些方法减少了样本大小和试验持续时间,提高了罕见病药物开发的效率.
科学领域:
- 临床药理学 临床药理学
- 生物统计学 生物统计学
- 瘤学 药物开发 药物开发
背景情况:
- 一期临床试验对于确定新药的最大耐受剂量至关重要.
- 罕见病试验面临的挑战是有限的患者招募,阻碍了传统的剂量发现设计.
- 现有的方法往往需要大样本大小,这在罕见疾病环境中往往是不可行的.
研究的目的:
- 提出新的剂量发现方案,剂量升级中的患者退缩 (PRIDE) 和PRIDE-FA,以解决罕见疾病I期试验中MTD识别挑战.
- 通过整合患者内剂量升级和灵活的分配策略来提高效率.
- 与现有方法相比,提高MTD选择准确性和减少资源需求.
主要方法:
- 开发了剂量升级中的患者退缩 (PRIDE) 方案,将随机效应纳入贝叶斯等级框架,以考虑患者内相关性.
- 引入了PRIDE-FA,这是PRIDE的扩展,具有灵活的患者分配策略,以提高资源效率.
- 将随机效应集成到已建立的设计 (CFO,BOIN,CRM) 中,以处理每个患者的多个剂量.
主要成果:
- 在模拟研究中,PRIDE和PRIDE-FA显著提高了MTD选择的准确性.
- 两种拟议的方法都显示了I阶段试验所需的样本大小的大幅减少.
- 与传统方法相比,PRIDE计划使总体试验时间显著缩短.
结论:
- PRIDE和PRIDE-FA为在罕见疾病中进行I期临床试验提供了强大而高效的框架.
- 这些新的设计有效地克服了与患者招募和样本大小有关的传统方法的局限性.
- 拟议的方法提高MTD的识别,优化资源利用,加快罕见病药物开发时间表.
更多相关视频
05:16Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
Published on: May 7, 2020
7.3K
04:05Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis
Published on: June 30, 2023
2.9K
相关概念视频
01:16Clinical Trials
10.8K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.8K
01:11Clinical Trials: Overview
5.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.0K
01:15Drug Dosing: Geriatric Patients
278
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
278
01:21Drug Dosing: Obese Patients
268
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
268
01:12Statistical Software for Data Analysis and Clinical Trials
1.6K
Statistical software is pivotal in data analysis and clinical trials by providing tools to analyze data, draw conclusions, and make predictions. These software packages range from simple data management applications to complex analytical platforms, supporting various statistical tests, models, and simulation techniques. Their significance lies in their ability to handle vast amounts of data with precision and efficiency, enabling researchers to validate hypotheses, identify trends, and make...
1.6K
01:24Chronic Kidney Disease II: Clinical Manifestations
664
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
664